Clinical Trial Detail

NCT ID NCT03138889
Title A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors (PROPEL)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Nektar Therapeutics
Indications

hepatocellular carcinoma

lung non-small cell carcinoma

melanoma

head and neck squamous cell carcinoma

transitional cell carcinoma

Therapies

NKTR-214 + Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST